Bodrogi I, Baki M, Sinkovics I, Eckhardt S
National Institute of Oncology, Budapest, Hungary.
Semin Surg Oncol. 1988;4(2):95-6.
In view of the divergent reports on the efficacy of ifosfamide in metastatic renal cell cancer, we tested this drug as monotherapy in nine patients on a dosage schedule of intravenous infusion of 40 mg/kg per day on days 1-5, repeated every 4 wk. The drug was administered in 1 liter saline dextrose over 2 hr, with hydration, alkalization of the urine, and mesna. No objective response was registered and subjective response in three patients was of short duration. The number of patients in this series is too small to draw definitive conclusions. However, the results obtained in this study does not prove antitumor activity for ifosfamide in renal cell cancer.
鉴于关于异环磷酰胺治疗转移性肾细胞癌疗效的报道存在分歧，我们对9例患者进行了该药物的单药治疗测试，给药方案为第1 - 5天每天静脉输注40mg/kg，每4周重复一次。药物在2小时内溶于1升生理盐水葡萄糖溶液中给药，并进行水化、尿液碱化及使用美司钠。未观察到客观缓解，3例患者的主观缓解持续时间较短。本系列研究的患者数量过少，无法得出明确结论。然而，本研究获得的结果并未证明异环磷酰胺对肾细胞癌具有抗肿瘤活性。
